Transl Androl Urol 2017;6(2):331-335 tau.amegroups.com © Translational Andrology and Urology. All rights reserved. both in the incident and recurrent disease settings. Pitfalls include obtaining sufficient high-quality DNA from all urine samples, dilution of tumour DNA (tDNA) with nontumour DNA, the heterogeneity of bladder cancer and, for surveillance, verifying biomarkers that are absolutely cancer specific, i.e., are not seen in any "field effect" (9) . The advantages and disadvantages of these approaches are summarised in Table 1 .
Disease heterogeneity requires that either multiple markers need to be measured for a broadly applicable test which detects as many tumours as possible (high sensitivity), or the biomarker test needs to be individualised to the characteristics of a patient's disease. The latter approach relies on the hypothesis that recurrent disease will retain the same genomic aberrations as the primary tumour (9, 14) . The former approach may require measuring a combination of alterations in copy number, methylation, and mutations at very low mutant allele frequencies; further technological innovation is needed to allow these diverse changes to be detected using a single analytical platform.
Two recent technologies that allow detection of very low levels of tDNA amongst a large excess of non-tumour DNA are droplet digital PCR (ddPCR) and next generation sequencing (NGS). ddPCR is ideal for detecting ultrarare alleles and gives absolute quantitation of the number of mutant alleles, but is limited in its ability to multiplex, i.e., large numbers of biomarkers cannot be assayed simultaneously. ddPCR is therefore ideal for developing individualized biomarker assays. Conversely, NGS is able to measure a large number of biomarkers (up to whole genome level), enabling the development of broad applicability tests, but is limited in its ability to detect very low mutant allele frequencies. With current technology and using high read depths, the lower of limit of detection of NGS is determined by the background noise and is of the order of 1% mutant allele frequency. NGS workflows that incorporate unique molecular identifiers (so that reads can be traced to original DNA molecules in the specimen) enable detection of one tDNA molecule amongst >1,000 wtDNA molecules (15) ; however, these approaches may be difficult to apply for multiple markers, especially when low nanogram quantities of DNA are available (as often occurs with urine), and require ultra-high read depths, thus increasing expense. Targeted NGS has been successfully used for the detection of mutations in FGFR3 and TERT individually, and as part of a 6-gene panel in urinary cell-pellet DNA (8, 13, 16) . It should be noted that low DNA yields from some urine specimens will provide only a few hundred/low thousand genome equivalents.
Whatever analytical approach is used, it is essential that the biospecimen contains sufficient tDNA to be detected, and urine DNA can be considered as two types which are easily separated by centrifugation or filtration: genomic DNA in exfoliated cells (the cell pellet) and cell-free DNA (cfDNA) in the supernatant/filtrate. We have observed that urinary cfDNA consists of slightly larger fragments than plasma cfDNA with a broad size distribution peaking between 200 and 300 bp, and a median concentration of 4 ng/µL in UBC patients (unpublished data). Two studies have directly compared the utility of urinary cell pellet DNA and urinary cfDNA for detecting bladder cancer using microsatellite analysis or copy number changes (6, 17) . Both found a higher proportion of tDNA relative to non-tumour DNA in the supernatant than in the cell pellet. This raises Table 1 The advantages and disadvantages of various approaches to the analysis of urinary tDNA
Method
Disadvantages Advantages DNA methylation Relatively large amount of DNA required Very high specificity and sensitivity recently reported (7) Influenced by other factors (age, smoking)
Copy number changes Unable to detect low levels of tumour DNA in a high background of non-tumour DNA High specificity and most UBCs have copy number changes (10) Microsatellite analysis Unable to detect low levels of tumour DNA in a high background of non-tumour DNA Good sensitivity and specificity reported (11) Multiple individual tests needed Mutations Multiple mutations must be analysed to achieve high sensitivity
High specificity and can detect low levels of tumour DNA in a high background of non-tumour DNA (8, 12, 13) tDNA, tumour DNA; UBCs, urothelial bladder cancers.
the fascinating proposition that the various biomarker assays that have previously worked well on cell pellet DNA might work even better on supernatant cfDNA. Furthermore, the size-based capture and enrichment of tumour cells may also improve the identification and analysis of urinary tDNA (18) , and the presence of circulating tumour cells have prognostic value (19) . In 2016, Birkenkamp-Demtröder et al. used NGS to detect chromosome breakpoints in the bladder tumours of 12 patients (20) . They subsequently designed ddPCR assays targeting these variants and assayed cfDNA isolated from longitudinally collected urine and plasma samples. The somatic variants were detectable in both the plasma and urine of patients, even in non-muscle-invasive bladder cancer (NMIBC) patients. The levels of tDNA dropped in patients post-treatment and high levels were predictive of progression.
The same group have now expanded on the urine and plasma cfDNA work with a ddPCR study of common FGFR3 and PIK3CA mutations (21) . Theoretically, these markers should be applicable for a large proportion of bladder cancer patients (especially those with low-grade NMIBC), although additional "personalised" markers based on tumour sequencing would have to be used for the remainder of patients [or, alternatively, a broader panel (8) ]. Initially, Christensen et al. tested over 800 formalin-fixed paraffin-embedded (FFPE) tumour tissues for the S249C and Y373C FGFR3 and E545K PIK3CA mutations, with 172 tumours testing positive (36% of NMIBCs and 11% of patients undergoing cystectomy); 54 of these patients were selected for subsequent urine and plasma cfDNA analysis, with selection based upon the availability of "liquid biopsies" and disease course characteristics. ddPCR data provide an absolute determination of the number of copies of mutant DNA per volume of body fluid. The absolute levels of mutant cfDNA in the urine of NMIBC patients were shown to be positively correlated with tumour stage, grade and size, although the association with European Organisation for Research and Treatment of Cancer (EORTC) risk category did not reach statistical significance (22) . In the NMIBC patient group (n=25), tDNA was not detected in plasma but a high initial level of urinary supernatant tDNA indicated future disease progression (P=0.036). In the cystectomy patient group (n=27), high urinary supernatant tDNA also appears to be a predictor of future recurrence (P=0.031); this effect is more pronounced with plasma tDNA/ctDNA (P<0.001). This is interesting research, although a number of aspects require clarification and further study. The small number of patients whose liquid biopsies were ultimately analysed were enrolled from 1992 to 2012, and so there is understandably a spectrum of treatment approaches over time. Intravesical Bacillus Calmette-Guérin (BCG) appears to have been utilised sparingly in those patients with T1 NMIBC, and cystectomy appears to have been applied inconsistently to those NMIBC patients who progressed to MIBC (3); furthermore, no patient undergoing cystectomy received neoadjuvant chemotherapy (23) . All of these treatment factors would have a significant influence on outcomes and, potentially, the persistence or re-emergence of tDNA, or the ability for mutations to be detected by the assay. And despite the urgent need for better prognostic biomarkers for HR-NMIBC patients, very few initial stage T1 patients were analysed (n=5). Furthermore, as the authors highlight, urinary supernatant tDNA may originate from renal clearance of tDNA in the circulation, and so the presence of the E545K PIK3CA mutation may not be bladder cancer specific (24) . In addition, the concept of "anticipatory" or "preemptive" diagnosis is a well-known pitfall in the field of non-invasive UBC diagnosis, whereby test specificity can be adversely affected by either the "field effect" and persistence of tumour-related abnormalities in the urine after clearance of disease (9), or by recurrent or residual disease that is not visible by white light cystoscopy (25) (26) (27) (28) (29) . These phenomena also have implications for prognostication. In this study the majority of NMIBC patients whose samples were selected for plasma and urinary tDNA analysis experienced recurrence or progression [ Figure 3 in the paper (21)]: only 2 of the 25 (8%) patients experienced sustained event-free survival at a median follow-up of 59 months, and neither had persistence of plasma or urinary tDNA after the tumour episode. By not studying more patients with such a prolonged event-free survival, the authors have perhaps missed an opportunity to demonstrate the frequency of urinary tDNA persistence in patients whose bladders have seemingly been successfully treated. The selected NMIBC patients also experienced a very high rate of residual disease: almost two-thirds of T1 episodes were seemingly followed by recurrence or progression at the next cystoscopy episode after treatment. Therefore, although the data show that the presence of urinary tDNA in NMIBC patients is significantly associated with progression of disease, it is equally likely to be indicative of inadequate treatment by resection and/or intravesical therapy. A contemporary cohort where patients receive current guideline-directed treatment may reveal a lower frequency of urinary tDNA post-treatment and during surveillance, but the relationship with subsequent progression may be more robust. And a similar phenomenon might be observed in patients treated with neoadjuvant chemotherapy prior to cystectomy.
In the future, utilising genome-wide or panel-based approaches for the analysis of plasma or urine tDNA may permit the near real-time monitoring of tumour evolution during intravesical therapy, neoadjuvant chemotherapy or chemoradiotherapy (6, 30) , possibly permitting adjustments to therapeutic approaches (Figure 1) .
However, despite its limitations, the authors of this study are to be commended on advancing the non-invasive characterisation of bladder cancer. Whilst it is a proof-ofprinciple study analysing a small number of patients and their liquid biopsies, it clearly points to a bright future for cfDNA-based tests in improving the management of bladder cancer patients (6) . The bladder cancer community should now focus on selecting the best biomarkers, optimising assay sensitivity, and large-scale validation of these novel tests. for survival, and so this illustration is a gross oversimplification.
